Table 1.
Characteristics of trials and trial population included in the analysis. For each racial category, the first column reports the study population. The second and third columns report descriptive statistics on the racial distribution across trials overall and within subcategories
| Trials | White participants | Black participants | Other participants* | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | Mean (SD) | Range | n (%) | Mean (SD) | Range | n (%) | Mean (SD) | Range | |
| Overall | 26 (100%) | 1,843 (80%) | 80% (13%) | 54%−100% | 381 (17%) | 15% (11%) | 0%−38% | 92 (4%) | 5% (7%) | 0%−37% |
| Intervention | ||||||||||
| Diet | 14 (54%) | 943 (81%) | 82% (12%) | 65%−100% | 159 (14%) | 14% (11%) | 0%−33% | 56 (5%) | 4% (4%) | 0%−14% |
| Exercise | 3 (12%) | 142 (86%) | 85% (13%) | 70%−94% | 16 (10%) | 11% (14%) | 2%−26% | 7 (4%) | 4% (2%) | 2%−6% |
| Combined diet and exercise | 7 (27%) | 448 (83%) | 76% (14%) | 54%−90% | 71 (13%) | 17% (11%) | 8%−38% | 24 (4%) | 7% (13%) | 0%−37% |
| Pelvic floor muscle training | 2 (8%) | 310 (69%) | 69% (7%) | 64%−75% | 135 (30%) | 30% (8%) | 24%−35% | 5 (1%) | 1% (0.4%) | 0.8%−1% |
| Primary funding source | ||||||||||
| Industry | 1 (4%) | 155 (85%) | - | - | 16 (9%) | - | - | 12 (7%) | - | - |
| NIH or other US government agency | 8 (31%) | 643 (71%) | 72% (12%) | 54%−94% | 217 (24%) | 19% (11%) | 0%−35% | 47 (5%) | 9% (12%) | 0.8%−37% |
| Non-profit organization | 1 (4%) | 48 (94%) | - | - | 2 (4%) | - | - | - | - | - |
| University | 16 (62%) | 997 (85%) | 82% (12%) | 63%−100% | 146 (12%) | 15% (12%) | 0–38% | 32 (3%) | 3% (3%) | 0%−8% |
| Disease stage | ||||||||||
| Localized | 19 (73%) | 1,300 (78%) | 79% (12%) | 63%−100% | 323 (19%) | 18% (12%) | 0%−38% | 52 (3%) | 4% (4%) | 0%−14% |
| Advanced | 7 (27%) | 543 (85%) | 83% (14%) | 54%−94% | 58 (9%) | 8% (5%) | 2%−19% | 40 (6%) | 8% (13%) | 0%−37% |
*
Other races reported include Hispanic, Asian/Pacific Islander, Native American/Alaskan Native, and Multi-racial